| Lymphoma |
FIL_V-RBAC, NCT03567876: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL |
|
|
| Active, not recruiting | 2 | 141 | Europe | Venetoclax, Venclyxto (commercial name) | Fondazione Italiana Linfomi - ETS, AbbVie | Lymphoma, Mantle-Cell | 07/21 | 07/25 | | |
| Completed | 2 | 34 | Europe, Canada, Japan, US, RoW | Tisagenlecleucel, CTL019, lymphodepleting chemotherapy, Bridging Therapy | Novartis Pharmaceuticals | Non-Hodgkin Lymphoma | 07/21 | 04/23 | | |
| Completed | 2 | 81 | RoW | IBI376, Parsaclisib | Innovent Biologics (Suzhou) Co. Ltd. | Indolent Non-hodgkin Lymphoma | 07/21 | 11/23 | | |
2021-001244-95: Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed Estudio de fase 2 de pembrolizumab y quimioterapia en pacientes con linfoma de Hodgkin clásico de reciente diagnóstico |
|
|
| Ongoing | 2 | 140 | Europe | Solution for infusion, Concentrate for solution for infusion, Powder for solution for injection, Powder for solution for infusion, Solution for injection, Capsule, Tablet, KEYTRUDA (pembrolizumab, MK-3475), Doxorubicin-Ebewe, Vinblastin STADA®, Detimedac® 500 mg, BLEO-cell®, ETOPOSIDE EBEWE®, ENDOXAN 1 g, Cellcristin® 1 mg/ml, Natulan, Prednison HEXAL®, ETOPOSIDE, Prednison HEXAL® 20 mg, Doxorrubicina, Dacarbazina, Etopósido, Ciclofosfamida, Procarbazina, Prednisona, Bleomicina, Vincristina | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc | Classical Hodgkin Lymphoma Linfoma de Hodgkin clásico, Classical Hodgkin Lymphoma (cHL) is a type of cancer of the lymphatic system, which is a part of your immune system. cHL can appear in the lymph nodes and other parts of the body. El linfoma de Hodgkin clásico (LHc) es un tipo de cáncer del sistema linfático, que forma parte de su sistema inmunitario. El LHc puede aparecer en los ganglios linfáticos y otras partes del cuerpo., Diseases [C] - Cancer [C04] | | | | |
NCT03502629: Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) |
|
|
| Recruiting | 2 | 86 | RoW | GB226, Recombinant humanized anti-PD-1 monoclonal antibody injection, Geptanolimab | Genor Biopharma Co., Ltd. | Peripheral T Cell Lymphoma | 08/21 | 12/22 | | |
NCT04062448: A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) |
|
|
| Completed | 2 | 16 | Japan | Ibrutinib, PCI-32765, Rituximab | Janssen Pharmaceutical K.K. | Waldenstrom Macroglobulinemia | 08/21 | 03/23 | | |
NCT03639181: Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) |
|
|
| Recruiting | 2 | 53 | RoW | GB226, Geptanolimab Injection | Genor Biopharma Co., Ltd. | B-cell Non-Hodgkin's Lymphoma | 09/21 | 12/22 | | |
2020-003735-16: A STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA |
|
|
| Not yet recruiting | 2 | 56 | Europe | Lacutamab, IPH4102, Solution for infusion | LYSARC, Innate Pharma | Relapsed/refractory PTCL KIR3DL2-positive patients after at least one previous line of systemic based regimen of chemotherapy, Relapsed/refractory patients with peripheral T-cell lymphoma, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 17 | Europe | Pembrolizumab, Rituximab | University College, London, Merck Sharp & Dohme LLC | Waldenstrom Macroglobulinemia | 09/21 | 06/23 | | |
2021-000870-27: A phase 2 trial to study safety and efficacy of Capivasertib in patients with blood cancer where disease or cancer cell grows after a period of remission or response to treatment does not last very long Ensayo de fase 2 para evaluar la seguridad y la eficacia del capivasertib en pacientes con cáncer de la sangre cuya enfermedad o las células del cáncer hayan vuelto a crecer tras un periodo de remisión o de respuesta al tratamiento de duración no muy prolongada |
|
|
| Not yet recruiting | 2 | 272 | Europe | Capivasertib, AZD5363, Tablet | AstraZeneca AB, AstraZeneca AB | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Linfoma no Hodgkin de células B en recidiva o refractario, Non-Hodgkin Lymphoma Linfoma no Hodgkin, Diseases [C] - Cancer [C04] | | | | |
2020-005197-10: Nanatinostat and Valganciclovir in R/R EBV+ Lymphoma (“NAVAL-1”) |
|
|
| Not yet recruiting | 2 | 150 | Europe | Nanatinostat, Valganciclovir, ganciclovir, VRx-3996, Film-coated tablet, Powder for concentrate for solution for infusion, Valganciclovir hydrochloride | Viracta Therapeutics, Inc., Viracta Therapeutics, Inc. | Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Diseases [C] - Cancer [C04] | | | | |
NCT01496976: Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL |
|
|
| Active, not recruiting | 2 | 45 | US | High Dose Methylprednisolone (HDMP), HDMP, Ofatumumab, Arzerra®, Lenalidomide, Revlimid®, IMiD® compound | H. Lee Moffitt Cancer Center and Research Institute, Novartis, Celgene Corporation | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 10/21 | 08/24 | | |
2020-004977-38: Study to determine the efficacy of Tafasitamab and lenalidomide administered in association with rituximab in frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or older . |
|
|
| Not yet recruiting | 2 | 71 | Europe | Tafasitamab, MOR208, Powder and solvent for solution for injection, Capsule, hard, Zelvina | LYSARC, Incyte | Frontline DLBCL, Diffuse Large B Cells Lymphoma, Diseases [C] - Cancer [C04] | | | | |
NCT02362997: Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL |
|
|
| Completed | 2 | 82 | US | Pembrolizumab, Keytruda, MK-3475, SCH 900475 | Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC | Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma | 10/21 | 06/23 | | |
2020-002622-87: A phase II trial of belimumab in combination withrituximab/venetoclax in patients with refractory orrelapsed chronic lymphocytic leukemia |
|
|
| Not yet recruiting | 2 | 120 | Europe | Benlysta 200 mg Injektionslösung im Fertigpen, n.a., Injection, Benlysta 200 mg Injektionslösung im Fertigpen Benlysta 200 mg Injektionslösung in einer Fertigspritze | University Hospital Tuebingen, GlaxoSmithKline | Refractory or relapsed chronic lymphocytic leukemia, Refractory or relapsed chronic lymphocytic leukemia, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 25 | Canada | DPX-Survivac, Pembrolizumab, Cyclophosphamide 50mg | Sunnybrook Health Sciences Centre, ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC | Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory Diffuse Large B-Cell Lymphoma | 10/21 | 07/23 | | |
|
|
|
NCT04615468: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL） |
|
|
| Not yet recruiting | 2 | 78 | RoW | TQ-B3525 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Peripheral T-cell Lymphoma | 10/21 | 10/22 | | |
2019-004613-14: Clinical trial conducted to evaluate the effectiveness of a combination of drugs called venetoclax and rituximab adapted to the state of minimal residual disease in patients with untreated chronic lymphocytic leukemia Badanie kliniczne prowadzone celem oceny skuteczności terapii kombinacją leków o nazwie wenetoklaks i rytuksymab dostosowanej do stanu minimalnej choroby resztkowej u pacjentów z do tej pory nieleczoną przewlekłą białaczką limfocytową |
|
|
| Not yet recruiting | 2 | 103 | Europe | Venetoclax, Rituximab, Film-coated tablet, Concentrate for solution for infusion, Venclyxto, MabThera | POLISH ADULT LEUKEMIA GROUP, AbbVie, Inc. | Chronic lymphocytic leukemia Przewlekła białaczka limfocytowa, Chronic lymphocytic leukemia is a type of tumor that affects lymphocytes and lymph nodes. In CLL, lymphocytes are produced faster and live longer, which is why their number in the blood is too large. Przewlekła białaczka limfocytowa jest rodzajem nowotworu oddziałującym na limfocyty i węzły chłonne. W PBL limfocyty są wytwarzane szybciej i żyją dłużej, dlatego ich liczba we krwi jest zbyt duża., Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 89 | Europe | Obinutuzumab Injection [Gazyva], Gazyvaro, Low dose radiation Therapy (LDRT) | Heidelberg University, Roche Pharma AG | Stage II Grade 1 Follicular Lymphoma, Stage II Grade 2 Follicular Lymphoma, Stage I Follicular Lymphoma Grade 1, Stage II Follicular Lymphoma Grade 2 | 11/21 | 05/24 | | |
2020-002142-17: Evaluation of a treatment with acalabrutinib in very old (≥80 years) or frail patients with chronic lymphocytic leukemia Beurteilung einer Therapie mit Acalabrutinib bei sehr alten (≥80 Jahre) oder gebrechlichen Patienten mit chronischer lymphatischer Leukämie |
|
|
| Not yet recruiting | 2 | 53 | Europe | Acalabrutinib/ ACP-196, Capsule, hard + tablet, Calquence | University of Cologne, AstraZeneca | Patients with CLL requiring treatment, Patients with chronic lymphocytic leukaemia in need of treatment, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 46 | Europe | Obinutuzumab, GA 101, Bendamustine, Bendamustine hydrochloride; Ribomustin | Prof. Dr. Wolfgang Hiddemann, Hoffmann-La Roche, Mundipharma Research GmbH & Co KG | Indolent Non-hodgkin Lymphoma | 11/21 | 12/22 | | |
LYTPET, NCT00324467: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment |
|
|
| Active, not recruiting | 2 | 150 | Canada | Cyclophosphamide, Cytoxan®, Neosar®, Doxorubicin, Adriamycin ®, Rubex®, Vincristine, Oncovin ®, Vincasar Pfs ®, Vincristine Sulfate, LCR, VCR, Prednisone, Sterapred®, Sterapred® DS, Prednisone Intensol, Ondansetron, Zofran®, Zofran® ODT, Zuplenz®, Dexamethasone, Decadron®, Dexamethasone Intensol®, Dexpak® Taperpak®, Diphenhydramine, Aler-Dryl®, Benadryl®, Nytol®, Diphenhist®, Acetaminophen, Tylenol®, Ifosfamide, Ifex®, Isophosphamide, Mesna (IV), Mesnex®, Sodium 2-mercaptoethanesulfonate, Mesna (oral), Carboplatin, CBDCA, Etoposide, Etopophos®, VP-16, Rituximab, Rituxan®, PET Scan, Positron emission tomography (PET) scan | British Columbia Cancer Agency, Hoffmann-La Roche | Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma | 12/21 | 12/21 | | |
NCT02242097: Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 37 | US | ibrutinib, Bruton's tyrosine kinase inhibitor PCI-32765, BTK inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, laboratory biomarker analysis | Northwestern University, Janssen Scientific Affairs, LLC, National Cancer Institute (NCI) | Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma | 01/23 | 01/25 | | |
| Active, not recruiting | 2 | 30 | US | romidepsin, FK228, FR901228, Istodax, lenalidomide, CC-5013, IMiD-1, Revlimid, laboratory biomarker analysis | Northwestern University, Celgene, National Cancer Institute (NCI) | Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome | 08/20 | 08/24 | | |
2016-004043-36: T cell therapy for patients with leukemia or lymphoma T cellsterapi för behandling av leukemi och lymfom. |
|
|
| Not yet recruiting | 2 | 25 | Europe | 3rd generation anti-CD19 CAR T cells, 3rdCARTa19, Solution for infusion | Uppsala University, AFA Insurance AB | CD19+ B cell lymphoma or leukemia CD19+ B cells-malignitet, Leukemia and lymphoma, blood cell cancer Leukemi och lymfom, blodcancer, Diseases [C] - Cancer [C04] | | | | |
2021-003397-32: A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectiveness of medication MK-2140 in patients with Diffuse Large B Cell Lymphoma who failed prior therapies. Estudio de investigación en el que los participantes y personal sanitario saben qué tratamiento se está recibiendo, para evaluar la seguridad y eficacia de MK-2140 en pacientes con linfoma difuso de células B grandes que no hayan respondido a terapias anteriores. |
|
|
| Not yet recruiting | 2 | 100 | Europe, RoW | Zilovertamab Vedotin, MK-2140, Solution for injection | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., Merck Sharp & Dohme LLC., a subsidiary of Merck & Co.,Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, | Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Tratamiento en participantes con linfoma difuso de células B grandes en recaída o resistente, Diffuse Large B Cell Lymphoma (a type of non-Hodgkin’s lymphoma, in patients who failed prior therapies) Linfoma difuso de células B grandes (un tipo de linfoma No Hodgkin) en pacientes que hayan fallado en terapias previas, Diseases [C] - Cancer [C04] | | | | |
NCT04149821: Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy |
|
|
| Terminated | 2 | 1 | US | Umbralisib, TGR-1202, Ublituximab, TG-1101 | Weill Medical College of Cornell University, TG Therapeutics, Inc. | Chronic Lymphocytic Leukemia, CLL Progression, CLL/SLL | 01/22 | 06/22 | | |
AVENT, NCT03439501: Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[ STUDY] |
|
|
| Active, not recruiting | 2 | 21 | RoW | avelumab | Samsung Medical Center, Merck KGaA, Darmstadt, Germany | Lymphoma, Extranodal NK-T-Cell | 01/22 | 03/22 | | |
2021-002150-91: A study of SAR444245 with or without other anticancer therapies for the treatment of adults and adolescents with relapsed or refractory B cell lymphoma (Master Protocol) Estudio de SAR444245 con o sin otros tratamientos antineoplásicos para el tratamiento de adultos y adolescentes con linfoma de células B en recaída o refractario (protocolo principal). |
|
|
| Ongoing | 2 | 60 | Europe | SAR444245, Concentrate for solution for infusion, Keytruda | Sanofi-Aventis Recherche & Développement, Sanofi-Aventis Recherche & Développement | Classic Hodgkin LymphomaDiffuse large B-cell lymphoma Linfoma de Hodgkin clasicoLinfoma difuso de células B grandes en recaída o refractario, Lymphoma Linfoma, Diseases [C] - Cancer [C04] | | | | |
NCT04539444: A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma |
|
|
| Recruiting | 2 | 10 | RoW | CD19/22 CART, Tislelizumab, PD-1 inhibitor | The First Affiliated Hospital of Soochow University, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | 02/22 | 02/23 | | |
NCT04477486: Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 6 | Japan | Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclexta, GDC-0199, Venclyxto | AbbVie | Mantle Cell Lymphoma (MCL) | 02/22 | 10/25 | | |
2021-002570-54: AZD4573 as Monotherapy or in Combination with Anti-cancer Agents in Patients with r/r PTCL or r/r cHL AZD4573 in monoterapia o in combinazione con agenti antitumorali in pazienti con PTCL r/r o cHL r/r |
|
|
| Not yet recruiting | 2 | 90 | Europe | AZD4573, [AZD4573], Concentrate for solution for injection/infusion | ASTRAZENECA AB, AstraZeneca AB | - Relapsed/refractory Peripheral T-cell Lymphoma- Relapsed/refractory Classical Hodgkins Lymphoma - Linfoma a cellule T periferico recidivante/refrattario- Linfoma di Hodgkin classico recidivante/refrattario, Cancer (lymphoma) Cancro (linfoma), Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
CTR20150541: A Phase II clinical study of AT-101 in the treatment of patients with chronic lymphocytic leukemia |
|
|
| Terminated | 2 | 92 | China | R-(-)-gossypol (AT 101) - Ascentage Pharma, Rituxan (rituximab) - Biogen, Zenyaku Holdings, Roche | Jiangsu Yasheng Pharmaceutical Development Co., Ltd. | Relapsed or refractory chronic lymphocytic leukemia (CLL) | | | | |
NCT04610970: A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） |
|
|
| Recruiting | 2 | 93 | RoW | TQ-B3525 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Diffuse Large B-cell Lymphoma | 03/22 | 06/22 | | |
| Active, not recruiting | 2 | 98 | Europe | Ibrutinib, Imbruvica, GA 101, Obinutuzumab | Ludwig-Maximilians - University of Munich, Hoffmann-La Roche, Janssen-Cilag G.m.b.H | Indolent Non-Hodgkin Lymphoma | 04/22 | 07/22 | | |
2020-003876-42: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL Aggiustamento terapeutico basato su PET/TAC e DNA tumorale circolante in pazienti con linfoma diffuso a grandi cellule B |
|
|
| Not yet recruiting | 2 | 260 | Europe | Acalabrutinib, [ACP-196], Capsule, hard | SAKK, AstraZeneca | Disseminated large B cell lymphoma Linfoma diffuso a grandi cellule B, Disseminated large B cell lymphoma Linfoma diffuso a grandi cellule B, Diseases [C] - Cancer [C04] | | | | |
NCT03436862: Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk |
|
|
| Completed | 2 | 37 | US | Nivolumab, Opdivo | SCRI Development Innovations, LLC, Bristol-Myers Squibb | Hodgkin Lymphoma | 05/22 | 04/23 | | |
| Completed | 2 | 108 | Europe, US, RoW | AFM13 | Affimed GmbH | Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides | 05/22 | 01/24 | | |
NCT04600947: Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 69 | RoW | LP002 | Taizhou HoudeAoke Biomedical Co., Ltd. | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | 05/22 | 05/23 | | |
2021-005861-41: A research study to evaluate the safety and effectiveness and dosing of Zilovertamab Vedotin with R-CHP in adults with DLBCL Un estudio en investigación para evaluar la seguridad y eficacia y la dosificación de Zilovertamab Vedotin con R-CHP en adultos con LDCBG. |
|
|
| Ongoing | 2 | 60 | Europe | zilovertamab vedotin, Endoxan, Doxorubicin-Ebewe, Prednisone, Truxima, MK-2140, Lyophilisate for solution for infusion, Powder for solution for injection, Concentrate for solution for infusion, Tablet, Endoxan, Doxorubicin-Ebewe, Prednison 50 mg GALEN, Truxima | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Diffuse Large B-cell Lymphoma (DLBCL) Linfoma difuso de linfocitos B grandes (LDCBG), Phase II dose confirmation study in diffuse large B-cell lymphoma Estudio fase II de confirmación de dosis en Linfoma difuso de linfocitos B grandes., Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 217 | Europe, Canada, US, RoW | Zanubrutinib, BGB-3111, Brukinsa, Obinutuzumab, Gazyva | BeiGene | Relapsed/Refractory Follicular Non-Hodgkin Lymphoma | 10/21 | 10/24 | | |
NCT03544723: Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. |
|
|
| Recruiting | 2 | 40 | US | Ad-p53, anti-PD-1/anti-PD-L1, nivolumab, pembrolizumab, atezolizumab, durvalumab | MultiVir, Inc. | Solid Tumor, Lymphoma | 06/22 | 12/22 | | |
AVENuE, NCT03617666: Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study |
|
|
| Active, not recruiting | 2 | 49 | Europe, RoW | Avelumab, Bavencio | University College, London, Pfizer | Hodgkin Lymphoma | 07/22 | 05/25 | | |
NCT04457869: A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) |
|
|
| Not yet recruiting | 2 | 43 | NA | F520 | Shandong New Time Pharmaceutical Co., LTD | Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | 07/22 | 01/23 | | |
NCT04457830: The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL). |
|
|
| Not yet recruiting | 2 | 105 | NA | F520 | Shandong New Time Pharmaceutical Co., LTD | Peripheral T Cell Lymphoma | 07/22 | 01/23 | | |
MIT, NCT04514393: Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma |
|
|
| Recruiting | 2 | 33 | RoW | Methotrexate, MTX, Ibrutinib, Imbruvica, Temozolomide, TMZ | Huiqiang Huang, Guangdong 999 Brain Hospital, Nanfang Hospital of Southern Medical University, Xian-Janssen Pharmaceutical Ltd. | Primary Central Nervous System Lymphoma, PCNSL, Non Hodgkin Lymphoma | 09/22 | 06/24 | | |
2021-003658-22: Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Estudio en fase II de plamotamab en combinación con tafasitamab más lenalidomida en comparación con tafasitamab más lenalidomida en linfoma difuso de células B grandes recidivante o resistente al tratamiento |
|
|
| Not yet recruiting | 2 | 240 | Europe | Plamotamab, Lenalidomide, MONJUVI, XmAb13676, Lenalidomide, Concentrate for solution for infusion, Capsule, hard, Powder for solution for infusion, MONJUVI | Xencor, Inc., Xencor, Inc. | Relapsed or refractory diffuse large B-cell lymphoma Linfoma difuso de células B grandes recidivante o resistente al tratamiento, A type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. Un tipo de linfoma no Hodgkin (LNH). El LNH es un cáncer del sistema linfático., Diseases [C] - Cancer [C04] | | | | |
Alternative-C, NCT05387616: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden |
|
|
| Active, not recruiting | 2 | 98 | Europe | Copanlisib, ALIQOPA™, Obinutuzumab, GAZYVARO® | Ludwig-Maximilians - University of Munich, Roche Pharma AG, Bayer | Follicular Lymphoma | 09/23 | 05/26 | | |
PrE0405, NCT03834688: Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age |
|
|
| Active, not recruiting | 2 | 33 | US | Venetoclax, GDC-0199, ABT-199, RO5537382, Bendamustine, Bendamustine hydrochloride, Rituximab, Chimeric anti-CD20 monoclonal antibody, Rituxan | PrECOG, LLC., Genentech, Inc. | Mantle Cell Lymphoma | 10/22 | 11/24 | | |
2021-005744-29: EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA ENSAYO DE EFICACIA Y SEGURIDAD DEL EPCORITAMAB CON O SIN LENALIDOMIDA COMO TRATAMIENTO DE PRIMERA LÍNEA PARA SUJETOS CON LINFOMA DIFUSO DE CÉLULAS B GRANDES |
|
|
| Not yet recruiting | 2 | 180 | Europe, RoW | Epcoritamab, Lenalidomide, GEN3013, Concentrate for solution for injection, Capsule, hard, If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2., RoActemra | Genmab A/S, GENMAB A/S, Genmab A/S, Genmab US, Inc. | B-cell Lymphoma Linfoma de linfocitos B, Lymphoma of B-cell origin Linfoma de origen de células B, Diseases [C] - Cancer [C04] | | | | |
NCT05007652: A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma |
|
|
| Completed | 2 | 64 | Japan | KRN125(pegfilgrastim), PLR001(plerixafor), KRN8601(filgrastim), PLR001(plerixafor) | Kyowa Kirin Co., Ltd. | Multiple Myeloma and Malignant Lymphoma | 10/22 | 10/22 | | |
| Active, not recruiting | 2 | 255 | Europe, US, RoW | brentuximab vedotin, Adcetris, SGN-35, doxorubicin, vinblastine, dacarbazine, G-CSF, filgrastim, pegfilgrastim, nivolumab, Opdivo | Seagen Inc., Bristol-Myers Squibb | Hodgkin Lymphoma | 11/22 | 06/26 | | |
|
2020-002140-22: Gonadal dysfunction in male long-term survivors of malignant lymphoma Nedsat seksualfunktion hos mænd tidligere behandlet for lymfekræft |
|
|
| Not yet recruiting | 2 | 150 | Europe | Gel in sachet, Testogel 50 mg, gel in sachet | Lars møller Pedersen, Department of Hematology, Herlev Hospital, Besins Healtcare | Hypogonadism, Low levels of testosterone in the blood, with symptoms corresponding the low serumlevel., Diseases [C] - Hormonal diseases [C19] | | | | |
| Completed | 2 | 81 | Europe, US, RoW | Tafasitamab, MOR00208, Lenalidomide, LEN, Revlimid® | MorphoSys AG | Diffuse Large B-cell Lymphoma | 11/22 | 04/23 | | |
|
|
|
|
|
|
|
|
|
|
|
|
| Active, not recruiting | 2 | 53 | Europe | Ibrutinib / Bortezomib / Rituximab, Imbruvica / Velcade / Mabthera | Christian Buske, University of Ulm, ClinAssess GmbH, Zentrum für Klinische Studien Ulm, Hoffmann-La Roche, Johnson & Johnson | Waldenstrom Macroglobulinemia | 11/22 | 09/29 | | |
NCT04324879: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) |
|
|
| Recruiting | 2 | 80 | RoW | TQ-B3525 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed / Refractory Follicular Lymphoma | 12/22 | 12/22 | | |
NCT04705090: A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma |
|
|
| Not yet recruiting | 2 | 90 | NA | YY-20394 treatment | Shanghai YingLi Pharmaceutical Co. Ltd. | PTCL | 12/22 | 06/23 | | |
ChiCTR2100044313: A single-arm, prospective, multi-center phase II clinical study of tislelizumab injection combined with R-CHOP in the treatment of primary mediastinal large B-cell lymphoma |
|
|
| Recruiting | 2 | 20 | China | tislelizumab injection combined with R-CHOP | Affiliated Tumor Hospital of Xinjiang Medical University ; Affiliated Tumor Hospital of Xinjiang Medical University, BeiGene (Shanghai) bio-pharmaceutical Co. , Ltd. | Primary mediastinal Large B-Cell Lymphoma. | | | | |
PCR, NCT05115409: Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL |
|
|
| Not yet recruiting | 2 | 27 | NA | Anti-PD-1 Antibody Plus Chidamide and Rituximab | Sun Yat-sen University, Chipscreen Biosciences, Ltd. | Relapsed or Refractory DLBCL | 12/22 | 12/24 | | |
| Completed | 2 | 229 | Europe, Canada, Japan, US, RoW | Elimusertib (BAY1895344) | Bayer | Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma | 12/22 | 09/23 | | |
| Active, not recruiting | 2 | 46 | Europe, US, RoW | Tislelizumab, BGB-A317 | BeiGene, Lymphoma Study Association | Classical Hodgkin Lymphoma | 12/22 | 09/24 | | |
| Completed | 2 | 334 | Europe | Pembrolizumab, MK-3475, KEYTRUDA | UNICANCER, National Cancer Institute, France, Ligue contre le cancer, France, Merck Sharp & Dohme LLC | Sarcoma, Ovarian Neoplasm, Central Nervous System Neoplasm, Thyroid Neoplasm, Carcinoma, Neuroendocrine, Neoplasms, Germ Cell and Embryonal, NK/T-cell Lymphoma | 12/22 | 12/23 | | |
NCT05328102: Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) |
|
|
| Terminated | 2 | 3 | Europe, US | Plamotamab, XmAb13676, Tafasitamab, Lenalidomide | Xencor, Inc. | Diffuse Large-cell B-cell Lymphoma | 02/23 | 02/23 | | |
| Active, not recruiting | 2 | 82 | RoW | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma | 09/21 | 09/24 | | |
|
| Recruiting | 2 | 30 | RoW | TQ-B3101 capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL) | 12/22 | 12/22 | | |
NCT04827004: A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma |
|
|
| Not yet recruiting | 2 | 30 | RoW | Anlotinib Hydrochloride Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Diffuse Large B-cell Lymphoma | 12/22 | 12/22 | | |
NCT05472610: Study of Efficacy of BZ019 in Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 36 | RoW | BZ019 | Shanghai Mengchao Cancer Hospital, Shanghai Cell Therapy Group Co.,Ltd | Large B-cell Lymphoma | 01/23 | 01/23 | | |
NCT05274997: A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma |
|
|
| Recruiting | 2 | 97 | US | YY-20394, Linperlisib | Shanghai YingLi Pharmaceutical Co. Ltd. | Peripheral T/NK Cell Lymphoma (R/R PTCL) | 01/23 | 12/23 | | |
NCT04052997 / 2018-002556-32: Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma |
|
|
| Completed | 2 | 117 | Europe, Canada, US, RoW | Camidanlumab Tesirine, ADCT-301 | ADC Therapeutics S.A. | Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | 01/23 | 01/23 | | |
2020-002935-30: Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with Mantle Cell Lymphoma. Venetoclax in Kombination mit Ibrutinib und Rituximab oder konventionelle Chemotherapie (Bendamustin) und Ibrutinib und Rituximab bei Patienten mit Mantelzell-Lymphoms. |
|
|
| Not yet recruiting | 2 | 150 | Europe | Film-coated tablet, IMBRUVICA®140 mg Filmtabletten, Venclyxto® 10 mg Filmtabletten, Venclyxto® 50 mg Filmtabletten, Venclyxto® 100 mg Filmtabletten | University Medical Center of the Johannes Gutenberg-University Mainz, AbbVie Inc., Janssen Pharmaceutica NV | Mantle Cell Lymphoma Mantelzell-Lymphom, malignant lymph node disease bösartige Lymphknotenerkrankung, Diseases [C] - Cancer [C04] | | | | |
NCT05222269: [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients |
|
|
| Terminated | 2 | 1 | Europe | 68Ga-PTF, 68Ga-PentixaFor | PentixaPharm GmbH | CNS Lymphoma | 01/23 | 01/23 | | |
ZUMA-14, NCT04002401: Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma |
|
|
| Completed | 2 | 27 | US | Axicabtagene Ciloleucel, Yescarta®, Rituximab, RITUXAN®, Fludarabine, Cyclophosphamide | Kite, A Gilead Company | Refractory Large B-cell Lymphoma | 01/23 | 01/23 | | |
|
|
| Terminated | 2 | 315 | Europe, Japan, US, RoW | NIR178, taminadenant, PDR001, spartalizumab | Novartis Pharmaceuticals | NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer | 02/23 | 02/23 | | |
NCT04434937: Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) |
|
|
| Completed | 2 | 42 | Japan | parsaclisib, INCB050465 | Incyte Biosciences Japan GK | Lymphoma | 02/23 | 10/23 | | |
2019-002930-35: CAR T cell treatment in Elderly Patients with First-Relapsed or Primary Refractory B-cell Non-Hodgkin Lymphoma |
|
|
| Not yet recruiting | 2 | 28 | Europe | Tisagenlecleucel, Injection, Kymriah® | Univeristy of Cologne, Novartis | malignant disease of lymphnodes especially refractory and non-responding aggressive non Hodgkin lymphoma; Diffuse large B cell lymphoma (DLBCL), refractory and non-responding aggressive B-cell Non-Hodgkin’s Lymphoma (aNHL), Diseases [C] - Cancer [C04] | | | | |
TIGER, NCT04161118: TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma |
|
|
| Terminated | 2 | 3 | Europe | CTL019 | University of Cologne, Novartis | Non Hodgkin Lymphoma | 02/23 | 02/23 | | |
NCT05319028: Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
|
|
| Terminated | 2 | 2 | US | Mivavotinib, CB-659 | Calithera Biosciences, Inc | Non-GCB/ABC Diffuse Large B-Cell Lymphoma, With and Without MyD88 and/or CD79B Mutations | 02/23 | 02/23 | | |
| Completed | 2 | 3 | RoW | ICP-022 | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma | 11/21 | 12/21 | | |
| Active, not recruiting | 2 | 201 | Europe, Japan | resminostat, 4SC-201, Placebo | 4SC AG | Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous | 03/23 | 06/24 | | |
| Active, not recruiting | 2 | 78 | Europe | Nivolumab, Opdivo® | University College, London, Bristol-Myers Squibb | Hodgkin Lymphoma | 03/23 | 02/26 | | |
| Active, not recruiting | 2 | 49 | US | MyoStrain®, Cardiac MRI Imaging Software, Intramyocardial Strain | Washington University School of Medicine, Myocardial Solutions | Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma, Leukemia, Myeloma, Lung Cancer | 07/24 | 07/24 | | |
CORAL, NCT05209308: Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL |
|
|
| Withdrawn | 2 | 42 | US | Zandelisib, ME-401, Rituximab, Rituxan, MabThera, Venetoclax, Venclexta | MEI Pharma, Inc., Kyowa Kirin, Inc. | CLL | 03/23 | 03/23 | | |
GEMSTONE-201, NCT03595657: A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL) |
|
|
| Completed | 2 | 80 | RoW | CS1001 | CStone Pharmaceuticals | Extranodal Natural Killer/T-Cell Lymphoma | 03/23 | 03/23 | | |
|
| Terminated | 2 | 169 | Europe, US, RoW | Zandelisib (ME-401) | MEI Pharma, Inc. | Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma | 03/23 | 03/23 | | |
NCT01243190: Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Completed | 2 | 45 | US | Ofatumumab, Arzerra | M.D. Anderson Cancer Center, GlaxoSmithKline | Chronic Lymphocytic Leukemia | 03/23 | 03/23 | | |
2021-001711-85: A prospective, international, multi-centre, open-label, phase II study investigating the utility of [68Ga]Ga-PentixaFor PET imaging in response assessment (evaluation of the tumour response to the applied therapy) of primary (primary tumour in brain) and isolated secondary (secondary tumour in brain after relapse of a primary tumour not located in the brain) CNS lymphoma patients |
|
|
| Not yet recruiting | 2 | 50 | Europe | [68Ga]Ga-PentixaFor, Powder for solution for injection | PentixaPharm GmbH, PentixaPharm GmbH | Central nervous system (CNS) lymphoma, A rare non-Hodgkin lymphoma in which malignant (cancer) cells from lymph tissue form in the brain and/or spinal cord or spread from other parts of the body to the brain and/or spinal cord, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | | | | |
2021-005950-27: Imaging study with brentuximab in patients with lymphoma Beeldvormend onderzoek met brentuximab bij patiënten met lymfeklierkanker |
|
|
| Not yet recruiting | 2 | 20 | Europe | [89Zr] - Brentuximab, Solution for injection | University Medical Center Groningen, Takeda Pharmaceutical Company Ltd | All patients with histologically proven CD30-positive (i.e. > 1% cells) lymphomas who will be treated with brentuximab vedotin, including:Hodgkin lymphoma, T-cell lymphoma, Cutaneous T-cell lymphoma, DLBCL Alle patiënten met histologisch bewezen CD30-positieve (d.w.z. > 1% cellen) lymfomen die zullen worden behandeld met brentuximab vedotin, waaronder: Hodgkin-lymfoom, T-cellymfoom, Cutaan T-cellymfoom, DLBC, Patients with Lymphoma Patiënten met lymfeklierkanker:, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05] | | | | |
NCT01811368: Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma |
|
|
| Active, not recruiting | 2 | 20 | US | rituximab, IDEC-C2B8, Mabthera, Rituxan, ibritumomab tiuxetan, Zevalin, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, total nodal irradiation, TLI, total lymphoid irradiation, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell, allogeneic hematopoietic stem cell transplantation, cyclosporine, cyclosporin, cyclosporin A, CYSP, Sandimmune, mycophenolate mofetil, Cellcept, MMF | Joseph Tuscano, Spectrum Pharmaceuticals, Inc | Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma | 04/23 | 12/23 | | |
| Recruiting | 2 | 102 | RoW | SHR1459 ；YY-20394, Gemcitabine-Oxaliplatin | Jiangsu HengRui Medicine Co., Ltd. | Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma | 04/23 | 10/23 | | |
NCT05286164: Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART |
|
|
| Recruiting | 2 | 30 | RoW | Eltrombopag | Tel-Aviv Sourasky Medical Center, Novartis | CART Treatment, B Cell Lymphoma | 04/23 | 04/24 | | |
2022-002579-12: First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-2 inhibitor with BTK inhibitor according to disease status of the young patient with high risk Chronic Lymphatic Leukemia Associazione di un inibitore di Bcl-2 e un anticorpo monoclonale in prima linea seguita dalla somministrazione del solo inibitore di Bcl-2 o dall'associazione dell'inibitore di Bcl-2 con un inibitore di BTK in base all'andamento della malattia del paziente giovane con Leucemia linfatica cronica ad alto rischio. |
|
|
| Not yet recruiting | 2 | 78 | Europe | Gazyvaro 1000 mg, Venclyxto 10 mg, Venclyxto 50 mg, Venclyxto 100 mg, Brukinsa, Bactrim, Lamivudina, Trimeton, Tachipirina, Decadron, Allopurinolo, [NA], [N.A.], Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Concentrate for solution for injection, Solution for injection, Buccal tablet | FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, BeiGene, Roche, Fondazione GIMEMA Franco Mandelli Onlus | Chronic Lymphocytic Leukemia Leucemia linfatica cronica, Form of cancer characterized by the abnormal proliferation of a particular type of cells present in the blood (lymphocytes) with consequent accumulation in various parts of the body Forma di cancro caratterizzata dalla proliferazione abnorme di un particolare tipo di cellule presenti nel sangue (linfociti) con conseguente accumulo in varie parti del corpo, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
| Completed | 2 | 131 | Canada, US | brentuximab vedotin, Adcetris; SGN-35, bendamustine, dacarbazine, nivolumab | Seagen Inc., Bristol-Myers Squibb | Hodgkin Disease, Peripheral T Cell Lymphoma | 04/23 | 09/23 | | |
|
|
|
|
|
NCT04849416: A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) |
|
|
| Active, not recruiting | 2 | 126 | RoW | LOXO-305, LY3527727, Pirtobrutinib | Eli Lilly and Company, Loxo Oncology, Inc. | Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Leukemia, Lymphocytic, Chronic, B-Cell | 04/23 | 04/25 | | |
ICING, NCT04763616: Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy |
|
|
| Recruiting | 2 | 37 | RoW | Isatuximab, Cemiplimab | Won Seog Kim, Sanofi | Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma, Refractory Natural Killer/T-cell Lymphoma | 04/23 | 04/26 | | |
PORT, NCT03385226 / 2017-000433-30: A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) |
|
|
| Active, not recruiting | 2 | 46 | Europe | Pembrolizumab, Chemical Abstract Service (CAS) number - 1374853-91-4, Radiotherapy | University College, London, Merck Sharp & Dohme LLC | Cutaneous T Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome | 09/23 | 09/24 | | |
| Active, not recruiting | 2 | 148 | Europe, Canada, Japan, US, RoW | Valemetostat Tosylate, DS-3201b | Daiichi Sankyo | Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma | 05/23 | 04/28 | | |
2022-003398-51: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dose R-CHOP Eine prospektive, multizentrische Phase-2-Studie zur chemotherapiearmen Kombination von Rituximab mit dem Antikörper-Wirkstoff-Konjugat Polatuzumab Vedotin und dem bispezifischen Antikörper Glofitamab bei zuvor unbehandelten Patienten mit aggressivem B-Zell-Lymphom über 60 Jahren, die für ein voll dosiertes R-CHOP nicht in Frage kommen |
|
|
| Not yet recruiting | 2 | 80 | Europe | Glofitamab, Obinutuzumab, Polatuzumab vedotin, Rituximab, RO7082859, RO5072759, RO5541077, RO0452294, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Columvi, GAZYVARO, Polivy, MabThera | Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Roche Pharma AG, Roche Austria GmbH | aggressive large B-cell lymphoma, aggressive large B-cell lymphoma, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 45 | US | IBRUTINIB, Imbruvica, Venetoclax, Venclexta | Dana-Farber Cancer Institute, AbbVie, Pharmacyclics LLC. | Waldenstrom Macroglobulinemia, MYD88 Gene Mutation | 06/22 | 02/28 | | |
| Not yet recruiting | 2 | 30 | NA | Camrelizumab, Rituximab, Cyclophosphamide, Hydroxyldaunorubicin, Vincristine, Prednisone | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Primary Extranodal Lymphoma, DLBCL | 06/23 | 12/24 | | |
| Recruiting | 2 | 39 | RoW | Tazemetostat | Hutchison Medipharma Limited | Relapsed/Refractory Follicular Lymphoma With EZH2 | 06/23 | 02/24 | | |
|
